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The immune system protects the organism against infections and the damage associated 
with them. The first line of defense against pathogens is the innate immune response. In 
the case of a viral infection, it induces the interferon (IFN) signaling cascade and eventually 
the expression of type I IFN, which then causes an antiviral state in the cells. However, 
many viruses have developed strategies to counteract this mechanism and prevent the 
production of IFN. In order to modulate or inhibit the IFN signaling cascade in their favor, 
viruses have found ways to interfere at every single step of the cascade, for example, 
by inducing protein degradation or cleavage, or by mediate protein polyubiquitination. 
In this article, we will review examples of viruses that modulate the IFN response and 
describe the mechanisms they use.
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iNTRODUCTiON
The mammalian immune system evolved to detect and fight viral infections effectively. The induc-
tion of type I interferon (IFN), predominantly IFN-α and IFN-β, forms the first line of defense. The 
type I IFN response consists of two parts. First, the cell produces type I IFN, when triggered by a 
viral stimulus. The IFN is then secreted and, in the second part of the response, it is sensed by the 
producing, as well as neighboring cells, resulting in the production of IFN-stimulated genes (ISGs) 
[reviewed in Ref. (1)].
Viruses, which have coevolved with their host, develop strategies to counteract the signaling 
cascades of the innate immune system and ensure their replication. Recently, several reviews were 
published, describing the innate immune evasion strategies of individual viruses or virus families, 
such as influenza virus (2, 3), Phleboviruses (4), Herpes viruses (5–7), Coronaviruses severe acute 
respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) (8), human immu-
nodeficiency virus (HIV) (9, 10), as well as multiple RNA viruses (11, 12). Moreover, there are 
recent articles that review how viruses prevent detection by pathogen recognition receptors (PRRs) 
(13, 14) and how viruses modulate innate immune signaling by use of viral deubiquitinases (15).
In this review, we will compare the different strategies viruses have developed to suppress innate 
immune signaling of individual components of the innate immune signaling cascade. Due to the 
tremendous amount of data in this field, we will focus on recent discoveries. Older studies were 
summarized in Ref. (16, 17).
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viRUS ReCOGNiTiON
Invading viruses are recognized by PRRs [reviewed in Ref. (14)]. 
The most important viral markers for the innate immune system 
are viral nucleic acids. The detection of viral DNA through the 
cGAS-Sting pathway and the counter measurements taken by 
viruses have been reviewed recently (18) and are not part of this 
review.
Viral RNAs, which are mostly double-stranded (ds-)RNA, 
are recognized by three PRRs: the endosomal toll-like receptor 3 
(TLR3), the cytoplasmic retinoic acid-inducible gene I (RIG-I)- 
like receptors (RLRs), and the nucleotide-oligomerization 
domain (NOD)-like receptors (NLRs) (19). TLR3 and the RLRs 
are important for inducing the type I IFN response, whereas NLRs 
have been shown to regulate interleukin-1β (IL-1β) maturation 
through activation of caspase-1 (20). The group of RLRs consists 
of RIG-I, melanoma differentiation-associated gene 5 (MDA5), 
and laboratory of genetics and physiology 2 (LGP2). The three 
receptors have a similar structure, all containing a caboxy-
terminal domain, which functions as a repressor domain (RD) 
in RIG-I and LGP2 (21) and a central helicase domain, but LGP2 
lacks the caspase activation and recruitment domains (CARDs) 
that function in signaling [reviewed in Ref. (19, 22)]. Both the 
helicase and the carboxy-terminal domain are required for RNA 
binding. RIG-1 and MDA-5 detect specific viral RNA PAMPs, 
while LGP2 negatively regulates RIG-I signaling and promotes 
RNA binding to MDA5 [reviewed in detail in Ref. (14)].
In unstimulated cells, RIG-I and MDA-5 are kept in a repressed 
state due to phosphorylations on serine and threonine residues in 
the CARDs and carboxy-terminal domains (23, 24). Upon bind-
ing of RNA, both RIG-I and MDA-5 undergo conformational 
changes, resulting in release of their CARDs (25, 26). Recruited 
phosphatases remove the phosphate residues, and E3 ubiquitin 
ligases attach Lys63-linked ubiquitin polymers onto the CARDs 
and C-terminal domain of RIG-I, which are important for RIG-I 
tetramerization (27–31).
RNA-bound RIG-1 then interacts with 14-3-3ε, a mito-
chondrial trafficking protein, and the TRIM25 ubiquitin ligase, 
which together transport RIG-I to the mitochondria (32). There 
the CARDs of RIG-I or MDA-5 interact with the CARD of the 
mitochondrial activator of virus signaling (MAVS, also known as 
IPS-1, VISA, and Cardif), which is an essential signaling adaptor 
protein. The activation of MAVS has recently been reviewed in 
detail in Ref. (33).
TLR3 interacts with TRIF, which serves as a molecular 
platform and forms physical interactions with several adaptor 
molecules (34). By interacting with upstream adaptors, TRIF 
undergoes conformational changes and recruits the downstream 
TNF receptor-associated factor (TRAF)3 and TRAF6 [reviewed 
in Ref. (35)]. The kinase receptor-interacting protein-1 (RIP-1) 
is part of both the signaling pathways downstream of TLR3 and 
RIG-I. It can interact with TRIF to induce NFκB activation (36). 
Moreover, the dsRNA-activated TLR3 can recruit TRIF, RIP-1, 
and Caspase-8 and induce apoptosis (37). Also, RIP-1 and its 
adaptor protein Fas-associated protein with death domain 
(FADD) are part of the signaling cascade downstream of RIG-I 
and MDA-5 and involved in the activation of the transcription 
factors interferon regulatory factor (IRF)3 and IRF7 (38). TRAF3 
serves as a linker between the upstream adaptor proteins (TRIF 
or MyD88 for TLRs and MAVS for RLRs) and the downstream 
signaling kinases TBK1/IKKε or IRAK1/IKKα. The recruitment 
of TRAF3 to the TLR or RLR signaling complexes activates the E3 
ligase activity of TRAF3, which then catalyzes its own K63-linked 
ubiquitinylation. Subsequent TRAF3 activates TBK1/IKKε or 
IRAK/IKKα [reviewed in Ref. (39)] (Figure 1).
Viruses target RIG-I directly or indirectly to block the type 
I IFN response. The phlebovirus Toscana Virus expresses a 
non-structural protein, which directly interacts with RIG-I and 
induces its proteasomal degradation (40, 41). Foot-and-mouth 
disease virus (FMDV) proteins Lpro, 3Cpro, and 2B increase the 
RIG-I mRNA expression but decrease the protein expression of 
RIG-I. Lpro and 3Cpro both induce RIG-I degradation, whereas the 
mechanism of how 2B reduces RIG-I protein levels has not been 
solved yet (42). Other viruses target RIG-I indirectly. Hepatitis B 
virus (HBV) induces miR146a, which then posttranscriptionally 
inhibits the expression of RIG-I and suppresses the production 
of type I IFN (43).
The dengue virus NS3 protein binds to 14-3-3ε and prevents 
the translocation of RIG-I to MAVS. The binding site on NS3 is 
a highly conserved phosphomimetic motif, which was verified 
by generation of a virus containing a mutation in this motif (44).
It has been proposed that in certain cell types RIG-I requires 
sentinels, such as the protein DDX60, which associates with RIG-I 
and promotes the RIG-I RNA-binding activity (45, 46). Other 
studies question DDX60 acting as a broadly active enhancer 
of antiviral responses (47, 48) and instead suggest that DDX60 
only functions in the antiviral response to specific viruses, such 
as hepatitis C virus (47). However, there are data indicating that 
influenza A virus and hepatitis C virus attenuate IFNβ-promoter 
activation by targeting the sentinel DDX60. Both viruses activate 
the epidermal growth factor (EGF) receptor, which in turn 
phosphorylates DDX60 on Tyr-793 and Tyr-796. This results 
in the attenuation of DDX60-dependent RIG-I activation. In 
addition, independent of its role as sentinel for RIG-I viral RNA 
recognition, DDX60 plays a role in viral RNA degradation (46) 
(Figure 1).
Mitochondrial activator of virus signaling is blocked by dif-
ferent viruses in various ways. The dengue virus protein NS4A 
targets MAVS, and the interaction prevents the binding of 
MAVS to RIG-I (49). The porcine reproductive and respiratory 
syndrome virus (PRRSV) 3C-like protease (3CLSP), by contrast, 
cleaves MAVS in a proteasome- and caspase-independent man-
ner at Glu268 (E268/G269). Both cleavage products fail to acti-
vate the type I IFN response (50). Likewise, the hepatitis C virus 
protein NS3-4A (51, 52), as well as the highly pathogenic porcine 
reproductive and respiratory syndrome virus (HP-PRRSV) 
protein nsp4 (53) have been shown to cleave MAVS and block 
RLR signaling. The porcine epidemic diarrhea virus (PEDV) also 
targets MAVS in small intestinal epithelial cells (IECs). However, 
the exact mechanism has not been solved yet (54) (Figure 1).
The SARS coronavirus protein ORF9b not only influences anti-
viral signaling but also alters host cell mitochondria morphology 
by inducing degradation of the dynamin-like protein (DRP1). 
MAVS becomes concentrated into small puncta in the presence 
FiGURe 1 | Activation of interferon regulatory factors and the counteractions taken by viruses. DsRNA is sensed by PRRs, which results in the activation 
of different adaptor proteins and the recruitment of TRAF3. TBK1 and/or IKKε are activated and phosphorylate IRF3 and/or IRF7, which then translocate into the 
nucleus to induce type I IFN expression. CSFV, classical swine fever virus; DENV, dengue virus; FMDV, foot-and-mouth disease virus; HBV, hepatitis B virus; 
HP-PRRSV, highly pathogenic porcine reproductive and respiratory syndrome virus; HSV-1, herpes simplex virus type 1; HTLV-1, human T-cell lymphotropic virus 
type I; KSHV, Kaposi’s sarcoma-associated herpesvirus; MERS-CoV, middle east respiratory syndrome coronavirus; PBoV, porcine bocavirus; PEDV, porcine 
epidemic diarrhea virus; PRRSV, porcine reproductive and respiratory syndrome virus; RRV, rhesus macaque rhadinovirus.
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of ORF9b (55). In addition, ORF9b triggers K48-linked ubiquit-
inylation of MAVS, by targeting the poly(C)-binding protein 2 
(PCBP2) and the HECT domain E3 ligase AIP4. Under normal 
conditions, PCBP2 controls MAVS levels by linking the AID4 E3 
ubiquitin ligase with MAVS (56). In addition to MAVS, also the 
levels of TRAF3 and TRAF6 are reduced by ORF9b. However, it 
is unlikely that TRAF3 and TRAF6 are targeted directly. More 
likely, they are degraded due to their interaction with MAVS (55) 
(Figure 1).
Human T-cell lymphotropic virus type I (HTLV-1) protein Tax 
disrupts innate immune signaling in multiple ways: it binds to the 
RIP homotypic interaction motif (RHIM) domains of RIP-1 and 
disrupts the interaction between RIP-1 and RIG-I or MDA-5 and 
the activation of the type I IFN promoter. Tax also binds to TRIF 
and thereby interrupts the TLR3 signaling cascade. Finally, Tax 
blocks the association between RIP-1 and IRF7, which resulted 
in repression of the IRF7 activity (57) (Figure 1).
Middle East respiratory syndrome coronavirus M protein 
interacts with TRAF3 and disrupts the interaction between 
TRAF3 and TBK1, which ultimately leads to a reduced IRF3 
activation. For the interaction with TRAF3, the N-terminal 
transmembrane domain of the MERS-CoV M protein is suffi-
cient (58), similar to what has been shown for SARS-CoV before 
(59) (Figure 1).
ACTivATiON OF TRANSCRiPTiON 
FACTORS AND iFN TRANSCRiPTiON
Triggering of the TLR3- and RLR-signaling cascade results in the 
activation of the transcription factors NFκB and IRF3/IRF7. In its 
inactive state, the transcription factor NFκB is complexed with its 
inhibitor IκB (60). Upon stimulation, IκB is phosphorylated by 
the IκB kinase (IKK) complex, which is composed of two catalytic 
subunits, such as IKKα and IKKβ, and a regulatory subunit, such 
as NFκB essential modulator (NEMO) (61). The phosphorylation 
of IκBα induces its polyubiquitination through the E3 ubiquitin 
ligase β-transducin repeat-containing protein (β-TrCP) and 
subsequent proteasomal degradation (62), allowing NFκB to 
translocate into the nucleus and induce the expression of target 
genes (63) (Figure 2).
FiGURe 2 | Activation of NFκB signaling and the counteractions taken by viruses. Triggering of TLR3 results in the activation of first TRAF6 and 
subsequently of IKK (consisting of NEMO, IKKα, and IKKβ). Together with β-TrCP, IKK mediates the ubiquitinylation of IκB, resulting in the release of NFκB. EAV, 
equine arteritis virus; EMCV, encephalomyocarditis virus; FMDV, foot-and-mouth diseases virus; PEDV, porcine epidemic diarrhea virus; PRRSV, porcine reproductive 
and respiratory syndrome virus.
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Encephalomyocarditis virus (EMCV) protein 3C cleaves 
TRAF family member-associated NFκB activator (TANK), which 
inhibits TRAF6-mediated NFκB activation, on Gln291. As a 
result, NFκB is activated and the unstable C-terminal fragment of 
TANK is subjected to proteasomal degradation (64). Also, other 
viruses express proteases that cleave TANK, although on other 
residues, such as porcine reproductive and respiratory syndrome 
virus (PRRSV) (TANK is cleaved by Nsp4), FMDV (protease 
3C cleaves TANK), and equine arteritis virus (EAV) (TANK is 
cleaved by Nsp4). Thus, TANK seems to be a common target of 
several positive RNA viral proteases (64) (Figure 2).
Several viruses have been shown to disrupt IFN signaling by 
cleaving NEMO. PEDV 3C-like protease, nsp5, cleaves NEMO 
at Gln231 (65), whereas the hepatitis A virus 3C protease (3Cpro) 
cleaves NEMO at Gln304 (66) and the picornavirus FMDV 
protease 3Cpro at Gln383, removing the C-terminal zinc finger 
domain from the protein (67). The human rotavirus has devel-
oped another way. Its non-structural protein 1 (NSP1) has been 
shown to inhibit the NFκB pathway by degrading β-TrCP and 
consequently stabilizing IκB (68) (Figure 2).
TANK-binding kinase 1 (TBK1) and inhibitor of κB kinase ε 
(IKKε) are classified as non-canonical serine/threonine kinases 
and are both able to induce IRF3 and IRF7 phosphorylation 
and subsequent dimerization (69–72). However, while TBK1 is 
constitutively expressed in most cell types, the expression of IKKε 
is more restricted (73). Upon stimulation, TBK1 and IKKε are 
recruited by adaptor proteins to signaling complexes to be acti-
vated by phosphorylation on Ser172 and both have been shown 
to be subjected to K63-linked polyubiquitination [reviewed in 
Ref. (73, 74)]. For TBK1, K63-linked polyubiquitination seems 
to be important for TLR- and RLR-induced IFN production, as 
ubiquitin chains might serve as a platform for the assembly of 
TBK1 signaling complexes. Moreover, deubiquitinases are able 
to terminate the TBK1-mediated pathway by cleaving the K63-
linked ubiquitin chains [reviewed in Ref. (74, 75)]. Activated 
TBK1/IKKε phosphorylates IRF3 and/or IRF7 in the cytosol at 
specific serine residues. This phosphorylation results in homo- or 
heterodimerization of IRF3 and IRF7 and nuclear translocation 
(76, 77). Interestingly, while IRF3 is constitutively expressed, 
IRF7 is expressed at low levels in most cell types and expression 
is induced upon IFN signaling. Therefore, in most cells, IRF7 
strongly enhances the production of IFN [reviewed in Ref. (78)]. 
Once phosphorylated IRF3 and/or IRF7 dimers have translo-
cated into the nucleus, they bind to the transcription coactivator 
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CREB-binding protein (CPB)/p300 (79, 80). Together with other 
factors, such as NFκB, they form the enhanceosome on the IFNβ 
promoter and induce the expression of type I IFN [reviewed in 
Ref. (76)].
The viral proteins that target TBK1 act by either blocking acti-
vation of TBK1 by MAVS or by inhibiting activation of IRF3 by 
TBK1. The MERS-CoV protein ORF4b blocks IFNβ production 
by binding to TBK1 and IKKε and suppressing the formation of a 
MAVS/IKKε complex (81). In addition to inhibiting TBK1/IKKε 
activation, ORF4b can also inhibit the production of IFNβ in the 
nucleus; however, the mechanism has not been solved yet (81). 
Recently, two herpes simplex virus proteins have been shown to 
target TBK1/IKKε and inhibit the phosphorylation of IRF3: ICP27 
(82) and VP24 (83). Also, dengue virus serotype 4 non-structural 
proteins NS2A and NS4B, as well as the NS2A and NS4B proteins 
of other Dengue viruses, inhibit the phosphorylation of TBK1 
(84) and PEDV N protein has been shown to interact with TBK1, 
hampering the association of TBK1 with IRF3 and preventing the 
activation of IRF3 activation (85). The human T-cell leukemia 
virus type 1 oncoprotein Tax has been shown to also interact with 
TBK1. However, studies came to contradicting results on how 
that influences the production of IFNβ. While one group showed 
that Tax activates TBK1 and the production of IFNβ (86), another 
group showed that Tax suppresses the IFN production by interac-
tion with TBK1 (87). Interestingly, when a recent study tested 
how the rabies virus P protein of street strains behaves compared 
to laboratory-adapted strains with regard to the induction of type 
I IFN, they found that both street strains and laboratory strains 
inhibit TBK1-mediated signaling, but only the P protein of street 
strains also interacts with and inhibits IKKε-inducible IRF3-
dependent IFNβ expression (88) (Figure 1).
Interferon regulatory factor 3 is targeted by many viruses 
to impair innate immune signaling. Most viruses inhibit the 
phosphorylation and thereby also the dimerization and trans-
location of IRF3, such as the porcine deltacoronavirus (89) or 
poliovirus (90). Hepatitis E virus protein ORF3 also suppresses 
IRF3 phosphorylation, but in an indirect way. It activates the 
signal regulator protein α (SIRP-α), which negatively regulates 
type I IFN induction (91). In contrast, porcine bocavirus (PBoV) 
NP1 protein does not affect IRF3 expression, phosphorylation, or 
nuclear translocation. Instead, it interacts with the DNA-binding 
domain of IRF3 and inhibits the DNA-binding activity (92). A 
very interesting way of how to circumvent the host innate immune 
response was found when studying gammaherpesviruses Kaposi’s 
sarcoma-associated herpesvirus (KSHV) and rhesus macaque 
rhadinovirus (RRV). They express several viral homologs to the 
IRFs, called viral IRFs (vIRFs). These vIRFs have found multiple 
ways to suppress type I IFN production. For KSHV, different 
strategies have been reviewed in Ref. (6). Recently, the RRV vIRF 
R6 has been shown to interact with the transcriptional coactiva-
tor CBP in the nucleus, similar to the KSHV vIRF1. As a result, 
CBP cannot form a complex with the phosphorylated IRF3, and 
the IFN expression is not induced (93–95). Interestingly, RRV R6 
is the first vIRF for which an association with the viron could be 
shown. Therefore, vIRF V6 can shut down the type I IFN response 
shortly after the cell was infected, rendering the cell more sus-
ceptible to infection (95). The PEDV protein nsp1 also targets 
CBP. Nsp1 induces CBP degradation in a proteasome-dependent 
manner and thereby interrupts enhanceosome assembly and the 
production of type I IFN (96) (Figure 1).
For most of these interactions, the molecular mechanisms 
have not been unraveled yet. A protein that has been shown to 
interact with and induce proteasomal degradation of IRF3 some 
time ago is classical swine fever virus (CSFV) Npro (97,  98). 
Recently, the molecular mechanism has been published. IRF3 
and Npro interact direct and form a soluble 1:1 complex. 
Moreover, it was shown that Npro interacts with the full-length 
IRF3, not with individual domains, and that Npro binds the 
constitutively active form of IRF3 in the presence of CPB. Thus, 
Npro interacts with both the monomer and the active IRF3 
dimer and likely targets both species for ubiquitinylation and 
proteasomal degradation (99).
Interferon regulatory factor 7 is targeted by two human 
enteroviruses, such as enterovirus 71 and enterovirus 68. They 
downregulate IRF7 by cleaving it with their protease 3c, leaving 
the cleavage products unable to induce IFN expression. While 
enterovirus 71 cleaves IRF7 once at Gln189–Ser190 (100), 
Enterovirus 68 cleaves it twice, the cleavage sites being Gln167 
and Gln189 (101). Moreover, megalocytivirus, a DNA virus that 
infects marine and freshwater fish, induces the expression of the 
host microRNA pol-miR-731, which then specifically suppresses 
the expression of IRF7 (102) (Figure 1).
TYPe i iFN SiGNALiNG
The type I IFNs act in an autocrine, paracrine, or systemic manner 
to stimulate antiviral responses. They are recognized by the IFNα/β 
receptor (IFNAR), which consists of the subunits IFNAR1 and 
IFNAR2 expressed on virtually all cell types (103). The interac-
tion of type I IFN with the receptor results in the phosphorylation 
and activation of the IFNAR1- and IFNAR2-associated tyrosine 
kinases tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), 
which then phosphorylate IFNAR tyrosine residues, resulting in 
the recruitment and activation of signaling molecules, such as 
the signal transducer and activator of transcription (STAT) family 
of transcription factors (104, 105). Upon activation, STAT1 and 
STAT2, together with IRF9, form the IFN-stimulated gene factor 
3 (ISGF3), which then translocates into the nucleus to induce 
transcription of ISGs [reviewed in detail in Ref. (106–108)].
Several viruses target IFNAR to prohibit IFN binding and 
signaling. Influenza virus induces the degradation of IFNAR1. 
Hemagglutinin (HA) triggers the phosphorylation and ubiquit-
inylation of IFNAR1, thus promoting protein degradation (109). 
Encephalitic Flaviviruses, such as tick-borne encephalitis virus or 
West Nile virus, inhibit IFNAR1 surface expression. Their protein 
NS5 binds the cellular dipeptidase prolidase (PEPD), which is 
involved in IFNAR1 maturation and accumulation, activation 
of IFNβ-stimulated gene induction, and IFN-dependent viral 
control. This interaction inhibits IFNAR1 intracellular traffick-
ing and glycosylation but does not promote IFNAR1 degradation 
(110) (Figure 3).
Both STAT1 and STAT2 are targeted by many viruses to 
suppress ISG induction. PEDV induces Stat1 ubiquitinyla-
tion and targets it for degradation in the proteasomes (111). 
FiGURe 3 | Type i iFN signaling and the counteractions taken by viruses. IFN binds to its receptor and thereby activates Tyk2 and Jak1, which then 
phosphorylate Stat1 and Stat2. Together with IRF9, Stat1 and Stat2 form the ISGF3, which translocates into the nucleus and induces the expression of ISGs. 
HMPV, human metapneumovirus; IBV, infectious bronchitis virus; JEV, Japanese encephalitic virus; LPMV, La Piedad Michoacán Mexico Virus; PEDV, porcine 
epidemic diarrhea virus; RSV, respiratory syncytial virus; SFTSV, severe fever with thrombocytopenia syndrome virus; VZV, varicella-zoster virus.
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Some viruses evolved to prevent the phosphorylation of Stat1 
or Stat2. The paramyxovirus La Piedad Michoacán Mexico 
Virus (LPMV) V protein binds to Stat2 and prevents the type 
I IFN-dependent phosphorylation and nuclear translocation 
of Stat1 and Stat2 (112). Similarly, human metapneumovirus 
(HMPV) protein SH impairs Stat1 expression, phosphoryla-
tion, and activation (113). Simian varicella virus not only 
inhibits Stat2 phosphorylation but also promotes degrada-
tion of IRF9 in a proteasome-dependent manner through its 
protein ORF63 (114). Also, infectious bronchitis virus (IBV) 
inhibits phosphorylation and nuclear translocation of Stat1. 
However, despite detailed analyses, it is unclear which viral 
protein is responsible. It was, however, shown that the acces-
sory protein 3a contributes to IBV resistance to type I IFN, 
although the target is unknown as well (115). In case of the 
human Parvovirus B19, it becomes evidently clear that both 
the virus and the immune system constantly evolve to prevail. 
While its protein NS1 suppresses Stat phosphorylation, the 
immune system senses the protein and triggers the production 
of type I IFN (116). SFTSV, an emerging tick-borne pathogen, 
developed multiple ways to prevent ISG induction. The viral 
non-structural protein NS impairs Stat1 expression, phospho-
rylation, and activation (117) and interacts with STAT2 and 
sequesters STAT1 and STAT2 into viral inclusion bodies, where 
they are trapped (118) (Figure 3).
The JAK-STAT signal transduction pathway is negatively 
regulated by the suppressor of cytokine signaling (SOCS) fam-
ily of proteins in form of a classical feedback loop (119, 120). 
Some viruses induce the expression of SOCS to take advantage 
of this mechanism to minimize the induction of ISGs. Japanese 
encephalitic virus (JEV) downregulates the expression of micro-
RNA miR-432, which then results in upregulated SOCS5 levels 
(121). Varicella-zoster virus (VZV) infection induces the expres-
sion of SOCS3 (122) and respiratory syncytial virus (RSV) non-
structural proteins NS1 and NS2 induce upregulation of SOCS1 
and SOCS3, which also inhibited the induction of chemokines 
(123) (Figure 3).
HOST SHUT OFF
Viruses fully depend on the translation machinery of the host cell 
for replication. Accordingly, they have evolved multiple ways to 
hamper host protein synthesis [reviewed in Ref. (124)]. One way 
is to shut off host protein synthesis. For some time, it was thought 
that Gamma- and Deltacoronaviruses do not induce host shutoff, 
such as Alpha- and Betacoronaviruses do. However, a recent 
study showed that the infectious bronchitis Gammacoronavirus 
induces host shutoff using its protein 5b. It seems like 5b is a func-
tional equivalent of nsp1, the host shutoff protein of Alpha- and 
Betacoronaviruses (125).
CONCLUSiON
Viruses evolved to have various strategies to circumvent the 
innate immune response by blocking the production of type I 
IFN or the expression of ISGs. While these diverse strategies may 
appear contradictory between viruses, several factors require 
consideration. For example, the use of clinical isolates versus 
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laboratory-passaged strains could yield different results, particu-
larly with RNA viruses that rapidly accumulate mutations due to 
error-prone RNA-dependent RNA polymerases. Moreover, the 
choice of cell line can greatly influence experimental outcomes, 
as many immortalized or transformed continual cell lines harbor 
mutations in critical innate immune signaling (126). Likewise, 
the use of genetic knockout versus knockdown cell lines or 
organisms can influence experimental outcomes, as can the 
experimental procedures themselves, particularly when endog-
enous interactions are disrupted with the use of overexpression 
approaches.
Studying the mechanisms used by viruses to prevent an 
immune response is of great importance for the development 
of new strategies to limit the sequelae of viral infections. 
Identification of key immune evasion proteins allows develop-
ment of antivirals to target these proteins. Alternatively, iden-
tification of key cellular antiviral pathways allows development 
of strategies to enhance these pathways to overwhelm incoming 
viruses. Information on key immune evasion factors further 
facilitates the engineering of safe and effective vaccine strains 
and designing strategies to target new emerging viruses from the 
same or closely related family.
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